Page 6 - Box Section Ref News Today

This Viewpoint examines approaches to addressing uncertainty as a means of achieving diagnostic excellence.

This Viewpoint discusses the differences in disease expression, communication challenges, how complexity confounds the diagnostic process, the risks of ageism,

This Viewpoint discusses the definitions of medical devices and low-risk general wellness products and examines the difficulties the difference between these ty

This Viewpoint outlines approaches to successfully make clinical diagnoses, including coaching medical students in critical thinking and decision-making, promot

This Viewpoint discusses the challenges to detecting sepsis in patients early in the disease course and suggests ways to improve the diagnosis and outcomes of s

This Viewpoint launches a series of articles that will explore the multiple dimensions of achieving diagnostic excellence in the 21st century.

This Viewpoint, part of a new JAMA series on diagnostic excellence, explores the meaning of diagnosis and the ultimate goal of using the diagnosis to provide in

The key objective of JAMA is “To promote the science and art of medicine and the betterment of the public health”; similar objectives and mission statements are

JAMA. 1 He brought with him experience as editor of Archives of Disease in Childhood and extensive clinical perspective and academic and research experience as a pediatrician at Boston Medical Center and Boston University School of Medicine. But most important, he brought to JAMA and the JAMA family of journals extraordinary vision and creativity, a commitment to absolute excellence, highest integrity and ethical principles, and an insatiable drive and unrelenting work ethic. The past 10 yea...

C. Buddy Creech, MD, MPH; Shannon C. Walker, MD; Robert J. Samuels, MBChB On December 11, 2020, the US reached an extraordinary milestone in the efforts to end the COVID-19 pandemic: the Food and Drug Administration authorized emergency use of the first COVID-19 vaccine, manufactured by Pfizer-BioNTech. Since then, 2 additional COVID-19 vaccines, Moderna and Janssen (Johnson & Johnson), have received Emergency Use Authorization in the US and, as of March 8, 2021, more than 31 million peop...